Bluebird Bio saw its share price plunge by more than one-third after temporarily and voluntarily suspending two clinical trials assessing its LentiGlobin gene therapy for sickle cell disease (SCD; bb1111), following reports that two participants in the earlier-phase study developed blood cancers—one of acute myeloid leukemia (AML), the other of myelodysplastic syndrome (MDS).
Researchers in Korea generated a new method for generating CHO cell lines with significantly higher productivity, efficiency, and stability.
Researchers have identified a potential strategy to protect against Alzheimer’s by increasing the clusterin (CLU) protein, which binds misfolded proteins.
This approach for transporting therapeutics into cells could open up new possibilities for treating neurological disorders and other conditions.
This GEN webinar will feature three presentations from leading experts in cell and gene therapy, from academia, biopharma, and biotech, who will share their vision…
GEN’s Julianna LeMieux and IPM’s Damian Doherty provide their final check in from the AACR 2025 meeting in Chicago.
On this episode of GEN Live, we’ll talk to experts in delivery with a focus on AAV vectors.
Velsera and Complete Genomics are expanding their ability to serve clinical labs with an end-to-end solution from sample to insight.
A potential strategy introduces an entirely new type of therapy capable of addressing previously ‘undruggable’ targets within the cells.
Trained on data covering 1.5 billion years of evolution, CZI’s new generative AI model probes cellular biology across species for therapeutic applications.
Senator Tammy Baldwin showed unwavering support for scientific funding when she accepted the AACR Distinguished Public Service Award.
